Patents
Literature
5 results about "Hinge region" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hinge region. a proline-rich portion of an immunoglobulin heavy chain between the Fc and Fab regions that confers mobility on the two Fab arms of the antibody molecule thereby allowing it to combine better with the two epitopes.
Modified antibody constant region
PendingUS20260176367A1Immunoglobulins against cell receptors/antigens/surface-determinantsDisulfide bondingEpitope
The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
Owner:CHUGAI PHARMA CO LTD
Recombinant opcml fusion protein optimizing opcml d1 domain homodimerisation and methods of use for cancer treatment
PendingUS20260146069A1Cell receptors/surface-antigens/surface-determinantsAntibody mimetics/scaffoldsDisulfide bondingProtein molecules
Presented herein is a recombinant OPCML-Fc fusion protein molecule and methods of its use in cancer treatment where the Fc portion of the fusion protein molecule is only the CH2CH3 portion and lacks the hinge region containing the disulfide bridges preventing dimerization of the Fc portion and optimizing dimerization of the OPCML the D1 domain.
Owner:PAPYRUS THERAPEUTICS INC
Anti-cMET antibody
The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and / or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region.The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Owner:PIERRE FABRE MEDICAMENT SAS
Hinge-modified IgG antibody compositions for protease resistance and fc-γ receptor binding and methods of making the same
ActiveUS12643942B2Polypeptide with localisation/targeting motifGenetically modified cellsReceptorIntravenous gammaglobulin
Provided herein are antibodies, recombinant proteins, and methods of use thereof including, for example, immunoglobulin G (IgG) antibodies and recombinant proteins including a Fab region and an Fc region connected through a hinge region, where the hinge region is resistant to cleavage by a protease. Also, provided herein, inter alia, are immunoglobulin G (IgG) antibodies and recombinant proteins including a Fab region and an Fc region connected through a hinge region, and where the Fc region has higher affinity for a ligand compared to a wildtype Fc.
Owner:CITY OF HOPE
Trispecific antibody and use thereof
The present invention relates to a trispecific antibody specifically binding to CD19, CD3, and CD28, which trispecific antibody contains a fragment derived from an IgD hinge region as a linker. The present invention also relates to the use of the trispecific antibody for treating tumors such as malignant hematological tumors.
Owner:CYTOCARES (SHANGHAI) INC